Rapid Fire ‐ Basic Science 2

s 211 parameters were further improved by finerenone, reaching statistical significance for LV compliance (BAY-MI 17.7± 0.6 and 1.76± 0.12 RVU/mmHg; p< .05 vs. VSMMR-/–MI). Moreover, while the decrease in basal LV tissue perfusion measured 2 months after MI (Sham 12.8± 0.6, CTL-MI 9.8± 0.6 ml/min/g; p< .05) was not modified in VSMMR-/–MI or BAY-MI (VSMMR-/–MI 8.3± 0.8 and BAY-MI 9.7± 0.7 ml/min/g), the decrease in LV coronary reserve (Sham: 5.13± 0.81, CTL-MI: 1.1± 0.5 ml/min/g; p< .05) was at least partially prevented in VSMMR-/–MI and by finerenone treatment (VSMMR-/–MI 4.6± 1.6, BAY-MI 3.6±0.7 ml/min/g). Conclusions. These results show that VSM MR is involved in the deterioration of coronary and cardiac functions during the development of HF. The non-steroidal MR antagonist finerenone specifically improves coronary and cardiac functions more markedly than specific vascular smooth muscle cells MR deletion.